Document Detail


Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.
MedLine Citation:
PMID:  23348972     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Characterization of bacterial populations in infectious respiratory diseases will provide improved understanding of the relationship between the lung microbiota, disease pathogenesis, and treatment outcomes.
OBJECTIVES: To comprehensively define lung microbiota composition during stable disease and exacerbation in patients with bronchiectasis.
METHODS: Sputum was collected from patients when clinically stable and before and after completion of antibiotic treatment of exacerbations. Bacterial abundance and community composition were analyzed using anaerobic culture and 16S rDNA pyrosequencing.
MEASUREMENTS AND MAIN RESULTS: In clinically stable patients, aerobic and anaerobic bacteria were detected in 40 of 40 (100%) and 33 of 40 (83%) sputum samples, respectively. The dominant organisms cultured were Pseudomonas aeruginosa (n = 10 patients), Haemophilus influenzae (n = 12), Prevotella (n = 18), and Veillonella (n = 13). Pyrosequencing generated more than 150,000 sequences, representing 113 distinct microbial taxa; the majority of observed community richness resulted from taxa present in low abundance with similar patterns of phyla distribution in clinically stable patients and patients at the onset of exacerbation. After treatment of exacerbation, there was no change in total (P = 0.925), aerobic (P = 0.917), or anaerobic (P = 0.683) load and only a limited shift in community composition. Agreement for detection of bacteria by culture and pyrosequencing was good for aerobic bacteria such as P. aeruginosa (κ = 0.84) but poorer for other genera including anaerobes. Lack of agreement was largely due to bacteria being detected by pyrosequencing but not by culture.
CONCLUSIONS: A complex microbiota is present in the lungs of patients with bronchiectasis and remains stable through treatment of exacerbations, suggesting that changes in microbiota composition do not account for exacerbations.
Authors:
Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  187     ISSN:  1535-4970     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-16     Completed Date:  2013-07-18     Revised Date:  2013-08-23    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1118-26     Citation Subset:  AIM; IM    
Affiliation:
Cystic Fibrosis and Airways Microbiology Research Group, School of Medicine, Dentistry, and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom. m.tunney@qub.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Bacterial Agents / therapeutic use*
Bronchiectasis / drug therapy*,  microbiology*
Cohort Studies
Cross-Sectional Studies
Female
Humans
Longitudinal Studies
Lung / microbiology*
Male
Metagenome*
Sputum / microbiology
Grant Support
ID/Acronym/Agency:
HL092964/HL/NHLBI NIH HHS; //Medical Research Council
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents
Comments/Corrections
Comment In:
Am J Respir Crit Care Med. 2013 May 15;187(10):1044-5   [PMID:  23675713 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide ...
Next Document:  ?2-Agonist Therapy in Lung Disease.